Skip to main content

Table 2 (abstract P294). See text for description

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

 

Metastatic Melanoma

Groups based on therapies after IL-2

IL-2 then IPI

IL-2 then aPD-1±IPI

N

81

56

mOS (months)

15.8

28.7

1-,2-,3-year survival (%)

64, 28, 18

96, 66, 35

Back to article page